ImmuPharma (LON:IMM) Stock Price Up 27.3% - Time to Buy?

Key Points

• ImmuPharma plc's stock price increased by 27.3% to a last traded price of GBX 12.60 ($0.17), with about 4.5 million shares traded, representing a 46% decline in volume from its average.
• The company reported a significant net margin of 3,519.56%, despite a challenging price-to-earnings ratio of -1,415.73, indicating ongoing financial instability.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program Lupuzor™ targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 27.3% during mid-day trading on Saturday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Trading Up 27.3%

The stock has a market cap of £63.34 million, a P/E ratio of -1,415.73 and a beta of 1.53. The company's fifty day simple moving average is GBX 7.92 and its 200-day simple moving average is GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.